A New Publication Is a Reason to Check, Not a Purchase Approval
On 14 September 2026, EFSA published scientific opinions on a fermentation-derived L-threonine additive and two L-isoleucine grades. Both opinions were adopted on 24 July 2026. The September development is their publication, not a new authorisation taking effect that day. EFSA threonine opinion, EFSA isoleucine opinion.
The European Commission explains that feed additives require authorisation before being placed on the market. Its online register links to the relevant authorisation regulations. A scientific opinion and the applicable authorisation are therefore separate evidence checks for a buyer. European Commission: feed additives.
Commercial interpretation: Treat these publications as a prompt to review the approval file behind an offer. Do not use a favourable headline as permission to order an unfamiliar grade, change a formulation or accept a supplier's claim that all similarly named materials are interchangeable.
Keep the Conclusions Attached to the Product
For the assessed threonine additive, EFSA identified skin and respiratory sensitisation concerns, could not conclude on eye irritation, and considered inhalation and skin exposure a risk. Its conclusion on safety for target animals was conditional on supplementation appropriate to nutritional needs. EFSA threonine opinion.
The isoleucine opinion covers grades containing at least 90% and 65% L-isoleucine. It considered use in feed safe at nutritionally appropriate amounts, but expressed concerns about use in drinking water. It could not conclude on eye irritation for the 65% grade. Those distinctions should not disappear in a summary labelled simply 'safe'. EFSA isoleucine opinion.
Commercial interpretation: Ask the technical reviewer to record both the conclusion and its boundaries. Keep product identity, concentration, intended application and handling review together. An approval file that preserves only the positive sentence is less useful than one that identifies exactly what remains conditional or unresolved.
Build an Offer-to-Evidence Match
The following purchasing workflow is GT Nutritions' commercial interpretation, not an instruction issued by EFSA.
Start with the precise product offered. Request its current technical data sheet, lot Certificate of Analysis, safety data sheet where applicable, manufacturing identity and supporting authorisation reference. Ask the supplier to explain how those documents relate to the quoted grade. Avoid filling gaps with documents for another concentration, production route or product family.
Use a comparison sheet with one line for each material under consideration. Record the offered designation, analytical basis, manufacturing reference, intended species and application, and the document used to support each point. If the supplier changes the offered source, return that line for review instead of carrying approval across automatically.
Make unresolved differences explicit. For example, if a quotation gives a concentration without saying whether it is a minimum or typical value, request clarification before comparing it with another offer. Keep the original document and the supplier's written clarification together so the purchasing team is not relying on an undocumented interpretation.
Separate Technical Review from Commercial Commitment
EFSA describes its role as scientific evaluation within the feed-additive authorisation process. A favourable opinion is followed by regulatory steps involving the Commission and Member States. EFSA: feed additives.
Commercial interpretation: Give the regulatory, formulation and purchasing checks separate owners. Ask the regulatory reviewer to confirm the applicable status and conditions for the exact product. Ask the nutrition team to approve the intended use. Ask operations to review handling requirements. Only then should purchasing treat the material as approved for the specified programme.
When negotiating an offer before those checks are complete, make its conditional status visible. Define what must be resolved before a purchase order is released and who can remove each condition. A supplier's loading deadline should not silently become a substitute for technical sign-off.
Do Not Rewrite the Protein Basket from One Opinion
Commercial interpretation: For buyers also sourcing meals, gluten products or yeast-derived feed materials, the useful lesson is disciplined qualification. These amino-acid opinions do not establish equivalence with those materials, approve a substitution ratio or demonstrate savings from a revised protein basket.
Request a formulation-led comparison before changing ingredient allocations. Have the technical team specify the evidence it needs on amino-acid contribution, analytical basis, digestibility and intended use. Do not infer that information from a crude-protein headline or from an assessment of a different product.
Keep the purchasing decision narrow enough to verify: an identified material, an approved use, a defined specification and an agreed shipment. Record who approved the change and retain the documents used at that time. For repeat orders, agree which changes require renewed review rather than assuming the initial decision covers every future source and grade.